PL378399A1 - Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma - Google Patents

Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Info

Publication number
PL378399A1
PL378399A1 PL378399A PL37839904A PL378399A1 PL 378399 A1 PL378399 A1 PL 378399A1 PL 378399 A PL378399 A PL 378399A PL 37839904 A PL37839904 A PL 37839904A PL 378399 A1 PL378399 A1 PL 378399A1
Authority
PL
Poland
Prior art keywords
cataracts
glaucoma
diagnosis
therapy
gene family
Prior art date
Application number
PL378399A
Other languages
Polish (pl)
Inventor
Florian Lang
Andreas Busjahn
Original Assignee
Florian Lang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Florian Lang filed Critical Florian Lang
Publication of PL378399A1 publication Critical patent/PL378399A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/166—Cataract
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/168—Glaucoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL378399A 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma PL378399A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10305212A DE10305212A1 (en) 2003-02-07 2003-02-07 Use of the sgk gene family for the diagnosis and therapy of cataracts and glaucoma

Publications (1)

Publication Number Publication Date
PL378399A1 true PL378399A1 (en) 2006-04-03

Family

ID=32730900

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378399A PL378399A1 (en) 2003-02-07 2004-02-05 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma

Country Status (13)

Country Link
EP (1) EP1663246A2 (en)
JP (1) JP2006519189A (en)
KR (1) KR20050114214A (en)
CN (1) CN1771039A (en)
AU (1) AU2004210416A1 (en)
BR (1) BRPI0407300A (en)
CA (1) CA2514703A1 (en)
DE (1) DE10305212A1 (en)
MX (1) MXPA05008394A (en)
PL (1) PL378399A1 (en)
RU (1) RU2005127808A (en)
WO (1) WO2004069258A2 (en)
ZA (1) ZA200506280B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755571A2 (en) * 2004-03-11 2007-02-28 MERCK PATENT GmbH Methods for interfering with fibrosis
RU2006135654A (en) * 2004-03-11 2008-09-10 Мерк Патент ГмбХ (DE) METHODS FOR MODULATION OF GLUTAMATE RECEPTORS FOR TREATMENT OF NEUROPSYCHIATRIC DISORDERS, INCLUDING THE APPLICATION OF SERUM AND KLUCKORTICOID KINASE MODULATORS
DE102004059781A1 (en) * 2004-12-10 2006-06-22 Sanofi-Aventis Deutschland Gmbh Use of serum / glucocorticoid-regulated kinase
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
JPWO2007037560A1 (en) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Therapeutic or diagnostic use of SGK2 gene
WO2007062101A2 (en) * 2005-11-22 2007-05-31 Mcgill University Intraocular pressure-regulated early genes and uses thereof
US20080153903A1 (en) * 2006-12-22 2008-06-26 Alcon Manufacturing, Ltd. Inhibitors of protein kinase c-delta for the treatment of glaucoma
DE102008029072A1 (en) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Substance, which inhibits serum and glucocorticoid dependent kinase 3, useful for the prophylaxis and/or treatment or diagnosis of age-related diseases e.g. arteriosclerosis, skin atrophy, myasthenia, infertility, stroke and kyphosis
AU2012209455B2 (en) * 2011-01-25 2017-05-04 Monell Chemical Senses Center Compositions and methods for providing or modulating sweet taste and methods of screening therefor
KR102357260B1 (en) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 Method for diagnosis and predict of diabetic neuropathy using micro-rna and kit therefor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508575A (en) * 1994-08-30 1998-08-25 ユニバーシティ オブ ダンディー Apoptosis inducer and application of the inducer in therapy
CA2222562A1 (en) * 1995-06-07 1996-12-19 Jeffrey N. Miner Method for screening for receptor agonists and antagonists
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
DE19708173A1 (en) * 1997-02-28 1998-09-03 Dade Behring Marburg Gmbh Cell volume regulated human kinase h-sgk
WO1999059559A1 (en) * 1998-05-15 1999-11-25 Joslin Diabetes Center Independent regulation of basal and insulin-stimulated glucose transport
ATE373676T1 (en) * 1998-12-14 2007-10-15 Univ Dundee METHOD FOR ACTIVATING SGK BY PHOSPHORYLATION.
US6399655B1 (en) * 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
DE19917990A1 (en) * 1999-04-20 2000-11-02 Florian Lang Medicament containing inhibitors of cell volume regulated human kinase h-sgk
WO2001004145A2 (en) * 1999-07-14 2001-01-18 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
US6416759B1 (en) * 1999-09-30 2002-07-09 The Regents Of The University Of California Antiproliferative Sgk reagents and methods
US20030236246A1 (en) * 2002-04-30 2003-12-25 Brazzell Romulus Kimbro Method for decreasing capillary permeability in the retina
DE10225844A1 (en) * 2002-06-04 2003-12-18 Lang Florian sgk and nedd as diagnostic and therapeutic targets

Also Published As

Publication number Publication date
WO2004069258A2 (en) 2004-08-19
ZA200506280B (en) 2006-05-31
WO2004069258A3 (en) 2005-02-24
DE10305212A1 (en) 2004-08-19
KR20050114214A (en) 2005-12-05
CN1771039A (en) 2006-05-10
JP2006519189A (en) 2006-08-24
RU2005127808A (en) 2006-05-27
EP1663246A2 (en) 2006-06-07
BRPI0407300A (en) 2006-02-07
CA2514703A1 (en) 2004-08-19
AU2004210416A1 (en) 2004-08-19
MXPA05008394A (en) 2005-10-05

Similar Documents

Publication Publication Date Title
IL291162A (en) Isolated human rpe cells and use thereof for the treatment of degenerative diseases of the retina
IL230242A (en) Retinal derivatives and methods for the use thereof for the treatment of visual disorders
HK1092367A1 (en) Combination therapy for the treatment of ocular neovascular disorders
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
EP1814909A4 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
EG24420A (en) Treatment of ophthalmic conditions
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
ZA200605555B (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular disease
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
SI1487828T1 (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
PL378399A1 (en) Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1773882A4 (en) Diagnosis and treatment of siglec-6 associated diseases
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003246592A1 (en) Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
GB0523964D0 (en) The treatment of ophthalmic diseases
AU2002329000A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of pik3r1
AU2003237143A8 (en) Diagnosis and treatment of glaucoma
AU2003263036A8 (en) Span-xb gene and protein for the diagnosis and treatment of cancer
GB0326066D0 (en) Inhibitors of a-synuclein aggregation for the treatment and/or diagnosis of a-synuclein-related diseases
AU2003234488A8 (en) Diagnosis of glaucoma
SI1670482T2 (en) Use of ciclesonide for the treatment of respiratory diseases

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)